D.A. Wallach Explains Why Biotech VC Is So Different
In this episode of Odd Lots, hosts Tracy Alloway and Joe Weisenthal welcome D.A. Wallach, former lead singer of Chester French and now a biotech investor, to explore the complex, high-risk world of biotech investing, the structural challenges in drug development, and the evolving role o
Sign up to read the full summary
Free AI-powered recaps of every episode, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.
Guest
D.A. Wallach
conversational on Odd Lots
Mentions
Books, people, and resources mentioned in this episode.
People
Companies
Products & Tools
Topics
Listen to This Episode
More from Odd Lots
Tracy and Joe Answer All Your Questions
Jerry Neumann on the Problem With Investing in AI Right Now
BlackRock's Rob Goldstein on the Next Megatrends in Finance
Inside Hudson River Trading's Blistering Token Burn
The Booming Business of Chinese Peptides
Henry Blodget on the Software Selloff Hysteria and the Problem for OpenAI
Related episodes
From other shows on similar topics.
The French Industrialist Betting on Robotics to Cure Disease (And the Ethical Line He Won’t Cross) | Ep. 316 with Hervé de Malliard President of Maison MGA
Founder's Story
OpenAI’s Big Reset + A.I. in the Doctor’s Office + Talkie, a pre-1930s LLM
Hard Fork
$10M Business ideas w/ The Most Interesting Guy In Tech
My First Million
Got Ozempic Breath? & Goblins Infiltrate ChatGPT
Morning Brew Daily
#2501 - Marc Andreessen
The Joe Rogan Experience
OpenAI Misses Targets, Codex vs Claude, Elon vs Sam Trial, Big Hyperscaler Beats, Peptide Craze
All-In with Chamath, Jason, Sacks & Friedberg
Get summaries like this every morning.
Free AI-powered recaps of Odd Lots and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.